HMGB1 and Kaposi's sarcoma: To address the limitations of the study exploring the involvement of HMGB1 in KS development using primary endothelial cells, we employed the CRISPR-Cas9 system to knock out (KO) HMGB1 in immortalized human endothelial cells known as HuARLT cells.